Hepatitis C News

AMSTERDAM — Unexpectedly high hepatocellular carcinoma recurrence rates were reported among patients who achieved sustained virologic response after receiving direct-acting antiviral therapy, according to data presented at the International Liver Congress.

AMSTERDAM — In this exclusive video from International Liver Congress, John Dillon, MD, from the University of Dundee, Scotland, discusses new pathways of care for patients with hepatitis C, particularly those who inject drugs.

AMSTERDAM — Achieving global elimination of hepatitis C requires actionable plans and changes on many levels of society from allowance of non-specialist prescribing to universal access, a group of experts explained at the International Liver Congress.

AMSTERDAM — All but one patient in a recent cohort treated with the novel regimen glecaprevir/pibrentasvir achieved sustained virologic response, according to data presented at the International Liver Congress.

AMSTERDAM — Understanding the impacts of fibrosis, drug–drug interactions with direct-acting antiviral therapies, and the pitfalls of immunosuppression can aid clinicians in treating liver transplantation candidates or recipients, according to data presented at the International Liver Congress.

AMSTERDAM — When adjusted for age and severity of liver disease, occurrence and recurrence of hepatocellular carcinoma after curing hepatitis C virus showed no difference between treatment with interferon or direct-acting antivirals, according to an expert at the International Liver Congress.

As we continue to see the success of direct-acting antiviral therapy in treating hepatitis C virus, we must be aware of any potential complications from the underlying liver disease after successful treatment, especially hepatocellular carcinoma.

From its inception, the concept of organ transplantation has drilled down to the fundamental ethics of practicing medicine. From initial concerns about donating organs from individuals who died of a cardiac event to the advent of living donation, the medical community questioned if this practice violates the basic tenet of the Hippocratic Oath: do no harm. Now the HCV community is moving steadily toward donation of HCV-positive organs into HCV-negative recipients, and a new set of questions arises.

The FDA has approved sofosbuvir and ledipasvir/sofosbuvir as supplemental applications for the treatment of hepatitis C in children aged 12 to 17 years, according to an FDA news release.

AMSTERDAM — While hepatitis C virus-positive liver donation into HCV-positive recipients solves a number of public health problems, donation into HCV-negative recipients remains controversial, according to a presenter at the International Liver Congress.